Cost-effective far more than the United States, BioNTech, CureVac, CRISPR stand out, and many Biotechs in Europe are rising

Pharmaceutical innovation competition knows no borders

This article focuses on the characteristics of biotechnology development and popular companies

In the field of biotechnology, this is a unique area

Europe, as the main region of global biotechnology, accounts for more than 20% of the global pharmaceutical market and is also an important market

In recent years, Europe has a number of emerging technology companies in the fields of cell and gene therapy, gene editing, siRNA and other fields that stand out in the

Overall, the European market is complex and fragmented, with London being the most important biotechnology cluster on the European continent, followed by the Triangle of the Upper Rhine River in Germany, the "Gene Valley" in Paris, France, the Denmark-Sweden Biovalley, and the Norvam Biomedical Science Park in

8 clusters of biotechnology distribution in Europe, Source: McKinsey

01 Value for money, BioNTech, CureVac once again activate global investors

In the global spread of the new crown pneumonia epidemic, the performance of European vaccine developers BioNTech and CureVac has once again allowed global investors to see the vitality and strength of European biotechnology research and development companies, and attracted more investment institutions to join the investment in the

The data shows that the flow of funds to institutional life sciences investment institutions is increasing

For example, France's Jeito Capital, announcing that its first fund, Jeito I, will eventually end at 534 million euros ($632 million), exceeding its initial target of 500 million euros, and Sofinnova Partners has completed a €445 million ($540 million) fundraising, focusing on late-stage biopharmaceutical and medtech investments, mainly covering European clinical-stage companies; And the LSP in the Netherlands raised the largest fund ever raised for €850 million, and Sweden's Eir Ventures announced the completion of a €122 million ($138 million) biomedical

In addition, U.

The reason why European biotechnology has been able to attract a wide range of investors from all over the world is due in part to the huge advantages

In addition, for investment institutions, the investment cost of high-quality assets in Europe is cheaper than in the United States, and usually provides investors with more lucrative returns

02 The stars are shining, and the small European country Biotech is rising

Europe's Biotech companies have achieved remarkable results, and Deloitte data shows that from 2015 to 2020, new products launched by emerging biotechnology have dominated the EMA, accounting for an average of 33%

According to the 20 top Biotech companies in Europe by 2022 selected by the labiotech.

In the field of cell and gene therapy, TreeFrog Therapeutics from France aims to improve the manufacture

The most representative in the field of gene editing is CRISPR Therapeutics

Representative companies in the field of immunotherapy include Genmab
from Denmark.
Genmab was founded in 1999, and just one year after its founding, Genmab was listed in Copenhagen and Frankfurt, raising about $226 million
in IPOs.
In July 2019, Genmab went public
on the NASDAQ.
Genmab has a class 4 antibody drug development platform, developing more than 20 pipelines in the clinical stage, and one of Genmab's approved drugs is the best-selling drug Darzalex
, developed in collaboration with Janssen.
In 2022, Genmab and its partner Janssen are awaiting FDA approval of the decision of teclistama to be used to treat antibody drugs
for multiple myeloma.

Also in this area is Argenx, a heavyweight biotechnology company from the Netherlands, which works to improve the quality
of life of patients with severe autoimmune diseases or cancer.
Argenx's SIMPLE antibody platform based on the llama immune system and three antibody Fc engineering technologies enable the development of novel, complex targets and improved efficacy of drug candidates
.
In 2021, Zai Ding Pharma acquired efgartigimod's exclusive development and commercialization rights
in Greater China with a total cooperative payment of US$175 million.

AI drug discovery platforms represent companies such as Exscientia, which can reduce the time of the drug discovery process from years to months
.
In 2021, Exscientia raised $350 million on the NASDAQ and is currently worth $1.
088 billion
.
The company is an important partner of many large pharmaceutical companies, such as SG, Bayer, Sanofi, etc
.

From the perspective of the geographical distribution of European Biotech companies, in addition to the above-mentioned familiar British, French, German and Swiss related companies, the biotechnology strength of many small European countries can not be underestimated, and it is becoming a key area
authorized by Chinese companies.

Belgium, for example, has not only the world's heavyweight R&D giants, but also promising star companies
in various fields.
In addition, Lithuania, a country with a population of less than 3 million, currently has more than 400 companies in the field of life sciences, and this number is growing
every year.
While the country is still an emerging hub for biotech entrepreneurship, Lithuania already has many rising stars
.
There is also Poland, although the country's pharmaceutical industry as a whole is more focused on traditional generic drug development, but there are also more and more companies that are beginning to develop biologics
.
At the same time, Polish-based Biotech is also developing entirely new technologies
around the treatment of cancer and autoimmune diseases.

The relevant content of this article refers to:

Mckinsey：《Biotech in Europe: A strong foundation for growth andinnovation》

Deloitte：《Deciding on the right path：How biotechs should expand in(to)Europe》

labiotech.
eu：《The 20 European Biotech Companies to Watch in 2022》

labiotech.
eu：《European Biotech Investors Cap Off Record Year in Fundraising》

sifted.
eu：《Call it techbio or biotech, more European VCs are betting on life sciences》